» Articles » PMID: 33137960

The Role of the Microbiome in Oral Squamous Cell Carcinoma with Insight into the Microbiome-Treatment Axis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Nov 3
PMID 33137960
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Oral squamous cell carcinoma (OSCC) is one of the leading presentations of head and neck cancer (HNC). The first part of this review will describe the highlights of the oral microbiome in health and normal development while demonstrating how both the oral and gut microbiome can map OSCC development, progression, treatment and the potential side effects associated with its management. We then scope the dynamics of the various microorganisms of the oral cavity, including bacteria, mycoplasma, fungi, archaea and viruses, and describe the characteristic roles they may play in OSCC development. We also highlight how the human immunodeficiency viruses (HIV) may impinge on the host microbiome and increase the burden of oral premalignant lesions and OSCC in patients with HIV. Finally, we summarise current insights into the microbiome-treatment axis pertaining to OSCC, and show how the microbiome is affected by radiotherapy, chemotherapy, immunotherapy and also how these therapies are affected by the state of the microbiome, potentially determining the success or failure of some of these treatments.

Citing Articles

Characterization of Salivary Microbiota in Japanese Patients with Oral Cancer.

Kumagai K, Ishikawa S, Iino M, Edamatsu K, Okuyama N, Yusa K Int J Mol Sci. 2025; 26(5).

PMID: 40076957 PMC: 11900280. DOI: 10.3390/ijms26052339.


Microbial signatures in head and neck squamous cell carcinoma: an in silico study.

Kavitha L, Kuzhalmozhi M, Priyadharsini J, Arun Kumar A, Umadevi K, Ranganathan K J Appl Oral Sci. 2025; 33:e20240392.

PMID: 39907412 PMC: 11816647. DOI: 10.1590/1678-7757-2024-0392.


The Bidirectional Impact of Cancer Radiotherapy and Human Microbiome: Microbiome as Potential Anti-tumor Treatment Efficacy and Toxicity Modulator.

Palkovsky M, Modrackova N, Neuzil-Bunesova V, Liberko M, Soumarova R In Vivo. 2024; 39(1):37-54.

PMID: 39740900 PMC: 11705129. DOI: 10.21873/invivo.13803.


Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy.

Gan M, Liu N, Li W, Chen M, Bai Z, Liu D Mol Cancer. 2024; 23(1):273.

PMID: 39696340 PMC: 11657557. DOI: 10.1186/s12943-024-02193-7.


Oral Microbial Changes in Oral Squamous Cell Carcinoma: Focus on , , and .

Lee Y, Jung J, Hong J Medicina (Kaunas). 2024; 60(11).

PMID: 39596938 PMC: 11596053. DOI: 10.3390/medicina60111753.


References
1.
Bartnicka D, Gonzalez-Gonzalez M, Sykut J, Koziel J, Ciaston I, Adamowicz K . Shields the Periodontal Killer from Recognition by the Host Immune System and Supports the Bacterial Infection of Gingival Tissue. Int J Mol Sci. 2020; 21(6). PMC: 7139284. DOI: 10.3390/ijms21061984. View

2.
Binder Gallimidi A, Fischman S, Revach B, Bulvik R, Maliutina A, Rubinstein A . Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model. Oncotarget. 2015; 6(26):22613-23. PMC: 4673186. DOI: 10.18632/oncotarget.4209. View

3.
Moffatt C, Lamont R . Porphyromonas gingivalis induction of microRNA-203 expression controls suppressor of cytokine signaling 3 in gingival epithelial cells. Infect Immun. 2011; 79(7):2632-7. PMC: 3191996. DOI: 10.1128/IAI.00082-11. View

4.
Li N, Ma W, Pang M, Fan Q, Hua J . The Commensal Microbiota and Viral Infection: A Comprehensive Review. Front Immunol. 2019; 10:1551. PMC: 6620863. DOI: 10.3389/fimmu.2019.01551. View

5.
She Y, Nong X, Zhang M, Wang M . Epstein-Barr virus infection and oral squamous cell carcinoma risk: A meta-analysis. PLoS One. 2017; 12(10):e0186860. PMC: 5655447. DOI: 10.1371/journal.pone.0186860. View